Ligne de temps
Hugo Mouquet
Responsable de Structure
09 oct. 2024
publication
Intestinal newborn regulatory B cell antibodies modulate microbiota communities.
Lire plus30 sept. 2024
publication
Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Lire plus02 sept. 2024
publication
Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.
Lire plus19 juil. 2024
publication
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.
Lire plus01 mai 2024
11 janv. 2024
publication
Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells.
Lire plus05 janv. 2024
event
Group de Reflexion SIDA (GRS) seminar: “New insights in the regulation of HIV expression and latency”
Lire plus13 déc. 2023
02 nov. 2023
publication
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells.
Lire plus25 oct. 2023
10 oct. 2023
10 oct. 2023
publication
HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria.
Lire plus06 oct. 2023
publication
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure.
Lire plus24 août 2023
news
New publication – Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller
Lire plus06 juil. 2023
publication
Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
Lire plus15 mars 2023
project
CoVariant – Comprendre les déterminants de l’immunité muqueuse et optimiser le diagnostic de l’infection aux variants du SARS-CoV-2
Lire plus14 févr. 2023
publication
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Lire plus03 févr. 2023
publication
Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
Lire plus21 déc. 2022
publication
Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters.
Lire plus21 déc. 2022
publication
Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters
Lire plus17 nov. 2022
publication
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Lire plus02 nov. 2022
event
Groupe de Reflexion SIDA (GRS) meeting: “Role of membraneless organelles in viral replication”
Lire plus01 nov. 2022
publication
Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2.
Lire plus19 sept. 2022
publication
The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
Lire plus27 août 2022
21 juil. 2022
event
Groupe de Reflexion SIDA (GRS) seminar: “Functional and structural studies of the T cell response against two major human viruses: HIV-1 and SARS-CoV-2”
Lire plus07 juil. 2022
publication
NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections.
Lire plus04 juil. 2022
publication
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Lire plus28 juin 2022
publication
SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but critical for productive class switch recombination.
Lire plus17 juin 2022
news
New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Lire plus01 juin 2022
publication
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Lire plus17 mai 2022
publication
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody.
Lire plus27 avr. 2022
publication
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Lire plus11 avr. 2022
publication
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers.
Lire plus08 avr. 2022
news
New publication – Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller
Lire plus12 mars 2022
publication
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.
Lire plus07 mars 2022
publication
Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.
Lire plus02 févr. 2022
02 févr. 2022
publication
Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.
Lire plus01 févr. 2022
15 déc. 2021
publication
SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation.
Lire plus22 oct. 2021
13 oct. 2021
17 sept. 2021
publication
Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.
Lire plus01 sept. 2021
publication
Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.
Lire plus18 août 2021
publication
Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission.
Lire plus14 août 2021
publication
A monocyte/dendritic cell molecular signature of SARS-CoV-2 related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis.
Lire plus08 juil. 2021
11 juin 2021
news
COVID-19: sensitivity of the Indian variant (B.1.617.2) to monoclonal antibodies and sera from convalescent and vaccinated individuals
Lire plus18 mai 2021
publication
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Lire plus01 mai 2021
publication
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
Lire plus19 avr. 2021
publication
Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis.
Lire plus18 avr. 2021
18 avr. 2021
18 avr. 2021
18 avr. 2021
01 janv. 2021
publication
CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues.
Lire plus16 déc. 2020
publication
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Lire plus01 déc. 2020
30 nov. 2020
publication
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
Lire plus20 oct. 2020
08 oct. 2020
news
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
Lire plus02 sept. 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Lire plus14 août 2020
06 août 2020
30 juin 2020
publication
Broadly neutralizing antibodies potently inhibit cell-to-cell transmission of semen leukocyte-derived SHIV162P3.
Lire plus24 juin 2020
publication
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.
Lire plus10 juin 2020
28 févr. 2020
publication
Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.
Lire plus05 févr. 2020
publication
Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.
Lire plus06 janv. 2020
04 juil. 2019
publication
TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses
Lire plus10 mai 2019
09 avr. 2019
publication
HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells
Lire plus08 avr. 2019
event
Groupe de Reflexion SIDA (GRS) seminar: “Determinants of HIV-1 broadly neutralizing antibody induction”
Lire plus04 mars 2019
31 janv. 2019
21 nov. 2018
event
Groupe de Reflexion SIDA (GRS) seminar: “Tissue-like 3D environment shape modes of HIV-spread”
Lire plus18 sept. 2018
event
Groupe de Réflexion SIDA (GRS) seminar: “Defining Correlates of Immunology using Systems Serology”
Lire plus01 août 2018
29 mai 2018
publication
Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity
Lire plus22 mai 2018
09 avr. 2018
publication
Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals
Lire plus27 févr. 2018
02 févr. 2018
30 nov. 2017
publication
Humanized mouse models to study pathophysiology and treatment of HIV infection.
Lire plus29 nov. 2017
publication
Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir
Lire plus31 oct. 2017
19 juin 2017
publication
What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1
Lire plus19 juin 2017
31 mai 2017
publication
HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection
Lire plus18 avr. 2017
06 avr. 2017
15 mars 2017
15 févr. 2017
25 janv. 2017
16 janv. 2017
14 déc. 2016
12 sept. 2016
29 juil. 2016
03 mars 2016
03 mars 2016
01 mars 2016
12 févr. 2016
07 sept. 2015
07 sept. 2015
29 juil. 2015
29 juil. 2015
11 juil. 2015
11 mai 2015
22 avr. 2015
21 avr. 2015
publication
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas
Lire plus18 févr. 2015
publication
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Lire plus07 févr. 2015
publication
Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient
Lire plus12 déc. 2014
publication
HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies
Lire plus17 sept. 2014
publication
Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies
Lire plus16 sept. 2014
25 août 2014
publication
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
Lire plus13 juin 2014
25 nov. 2013
30 oct. 2013
publication
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Lire plus16 sept. 2013
publication
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
Lire plus13 sept. 2013
03 avr. 2013
28 mars 2013
publication
Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
Lire plus30 oct. 2012
publication
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
Lire plus24 oct. 2012
publication
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Lire plus23 juil. 2012
publication
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
Lire plus30 avr. 2012
publication
Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice
Lire plus04 janv. 2012
02 nov. 2011
24 oct. 2011
publication
Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells
Lire plus08 sept. 2011
publication
Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses
Lire plus14 juil. 2011
publication
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
Lire plus30 sept. 2010
publication
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
Lire plus02 août 2010
publication
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness
Lire plus10 mars 2010
publication
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity
Lire plus10 août 2009
01 mai 2009
publication
ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus
Lire plus15 mars 2009
publication
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Lire plus25 déc. 2008
publication
A method for identification of HIV gp140 binding memory B cells in human blood
Lire plus14 sept. 2008
publication
Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay
Lire plus19 juin 2008
publication
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses
Lire plus10 mars 2008
01 août 2007
01 nov. 2006
01 nov. 2006
publication
A truncated alternative spliced isoform of human desmoglein 1 contains a specific T cell epitope binding to the pemphigus foliaceus-associated HLA class II DRbeta1*0102 molecule
Lire plus01 sept. 2006
publication
Proteomic analysis of the autoantibody response following immunization with a single autoantigen
Lire plus01 juin 2005
01 mars 2005
01 juil. 2004
publication
Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus
Lire plus01 févr. 2003